Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bony M - Stereotactic Ablative Radiotherapy (SABR) of Bony Metastases in Patients With Oligometastatic Disease - A Phase II Study

NCT05101824 is registered in ClinicalTrials.gov with Gitte Fredberg Persson MD PhD as lead sponsor.

NCT NCT05101824
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05101824 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bony M - Stereotactic Ablative Radiotherapy (SABR) of Bony Metastases in Patients With Oligometastatic Disease - A Phase II Study
Lead sponsor
Gitte Fredberg Persson MD PhD
Phase
Not applicable
Overall status
Active, not recruiting
Start date
November 1, 2019
Completion date
November 1, 2027
Enrollment
67 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

bone metastases, oligometastatic disease, stereotactic body radiotherapy